Pain, Agitation/Sedation, Delirium, Immobility, Sleep Disruption, and Neuromuscular Blockade

Zaal IJ, Devlin JW, Hazelbag M, et al. Benzodiazepine-

Med.

2015;41(12):2130-2137.

https://doi.org/10.1007/

s00134-015-4063-z

Zaal IJ, Devlin JW, Peelen LM, Slooter AJ. A system-

atic review of risk factors for delirium in the ICU. Crit

ccm.0000000000000625

Duning T, van den Heuvel I, Dickmann A, et al.

Hypoglycemia

aggravates

critical

illness-induced

neurocognitive

dysfunction.

Diabetes

Care.

2010;33(3):639-644. https://doi.org/10.2337/dc09-1740

Hermans G, Wilmer A, Meersseman W, et al. Impact

of intensive insulin therapy on neuromuscular complica-

tions and ventilator dependency in the medical intensive

489. https://doi.org/10.1164/rccm.200605-665oc

Herridge MS, Cheung AM, Tansey CM, et al. One-year

outcomes in survivors of the acute respiratory distress

syndrome. N Engl J Med. 2003;348(8):683-693. https://

doi.org/10.1056/nejmoa022450

Herridge MS, Tansey CM, Matté A, et al. Functional

disability 5 years after acute respiratory distress syn-

drome. N Engl J Med. 2011;364(14):1293-1304. https://

doi.org/10.1056/nejmoa1011802

Hopkins RO, Suchyta MR, Snow GL, Jephson A,

Weaver LK, Orme JF. Blood glucose dysregulation

and cognitive outcome in ARDS survivors. Brain Inj.

2010;24(12):1478-1484. https://doi.org/10.3109/0269905

2.2010.506861

Jackson JC, Pandharipande PP, Girard TD, et al.

Depression, post-traumatic stress disorder, and func-

tional disability in survivors of critical illness in the

Respir Med. 2014;2(5):369-379. https://doi.org/10.1016/

s2213-2600(14)70051-7

Sevin CM, Bloom SL, Jackson JC, Wang L, Ely EW,

Stollings JL. Comprehensive care of ICU survivors:

development and implementation of an ICU recov-

org/10.1016/j.jcrc.2018.02.011

Stollings JL, Bloom SL, Huggins EL, Grayson SL,

Jackson JC, Sevin CM. Medication management to

ameliorate post-intensive care syndrome. AACN Adv

aacnacc2016931

Stollings JL, Bloom SL, Wang L, Ely EW, Jackson

JC, Sevin CM. Critical care pharmacists and medi-

cation management in an ICU recovery center.

org/10.1177/1060028018759343

Stollings JL, Caylor MM. Postintensive care syndrome

Pharm. 2015;72(15):1315-1323. https://doi.org/10.2146/

ajhp140533

Stollings JL, Poyant JO, Groth CM, et al. An inter-

national, multicenter evaluation of comprehensive

medication management by pharmacists in ICU recov-

https://doi.org/10.1177/08850666231176194

Van den Berghe G, Schoonheydt K, Becx P, Bruyninckx

F, Wouters PJ. Insulin therapy protects the cen-

tral and peripheral nervous system of intensive care

patients. Neurology. 2005;64(8):1348-1353. https://doi.

org/10.1212/01.wnl.0000158442.08857.fc

Neuromuscular Blocking Agents

Greenberg SB, Vender J. The use of neuromuscular

blocking agents in the ICU: where are we now?. Crit

ccm.0b013e31828ce07c

Hraiech S, Dizier S, Papazian L. The use of paralytics in

patients with acute respiratory distress syndrome. Clin

Chest Med. 2014;35(4):753-763. https://doi.org/10.1016/j.

ccm.2014.08.012

Huang DT, Angus DC, Moss M, et al. Design and ratio-

nale of the reevaluation of systemic early neuromuscular

blockade trial for acute respiratory distress syndrome.

org/10.1513/annalsats.201608-629ot

Lagneau F, D’honneur G, Plaud B, et al. A comparison of

two depths of prolonged neuromuscular blockade induced

by cisatracurium in mechanically ventilated critically

https://doi.org/10.1007/s00134-002-1508-y

Murray MJ, DeBlock H, Erstad B, et al. Clinical

practice guidelines for sustained neuromuscular